228 related articles for article (PubMed ID: 9110845)
1. Nursing management of MS patients receiving interferon beta-1b therapy.
Costello K; Conway K
Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
[TBL] [Abstract][Full Text] [Related]
2. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis pathways: an innovative nursing role in disease management.
Madonna MG; Keating MM
J Neurosci Nurs; 1999 Dec; 31(6):332-5. PubMed ID: 10726241
[TBL] [Abstract][Full Text] [Related]
4. The role of interferons in the treatment of multiple sclerosis.
Kelley CL
J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
[TBL] [Abstract][Full Text] [Related]
5. Betaseron: the new MS treatment.
Kelley CL; Smeltzer SC
J Neurosci Nurs; 1994 Feb; 26(1):52-6. PubMed ID: 8195651
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
[No Abstract] [Full Text] [Related]
9. Interferon beta-1b: latest published results, 1995.
Noseworthy JH
Mult Scler; 1996 Jul; 1(6):313-6. PubMed ID: 9345406
[TBL] [Abstract][Full Text] [Related]
10. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
11. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Rudick RA
Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
14. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Frese A; Bethke F; Lüdemann P; Stögbauer F
Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
[No Abstract] [Full Text] [Related]
15. Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients.
Tilbery CP; Mendes MF; Oliveira BE; Thomaz RB; Kelian GR
Arq Neuropsiquiatr; 2006 Mar; 64(1):51-4. PubMed ID: 16622553
[TBL] [Abstract][Full Text] [Related]
16. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
Portaccio E; Amato MP
CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
18. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
20. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
